ArticleHaematologica2019

Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study.

Marie Luise Hütter-Krönke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.